vs

Side-by-side financial comparison of MYERS INDUSTRIES INC (MYE) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.

MYERS INDUSTRIES INC is the larger business by last-quarter revenue ($204.0M vs $103.7M, roughly 2.0× Twist Bioscience Corp). MYERS INDUSTRIES INC runs the higher net margin — 5.6% vs -29.4%, a 35.0% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 0.0%). MYERS INDUSTRIES INC produced more free cash flow last quarter ($18.9M vs $-34.8M).

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid ...

Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.

MYE vs TWST — Head-to-Head

Bigger by revenue
MYE
MYE
2.0× larger
MYE
$204.0M
$103.7M
TWST
Growing faster (revenue YoY)
TWST
TWST
+16.8% gap
TWST
16.9%
0.0%
MYE
Higher net margin
MYE
MYE
35.0% more per $
MYE
5.6%
-29.4%
TWST
More free cash flow
MYE
MYE
$53.7M more FCF
MYE
$18.9M
$-34.8M
TWST

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MYE
MYE
TWST
TWST
Revenue
$204.0M
$103.7M
Net Profit
$11.3M
$-30.5M
Gross Margin
33.2%
52.0%
Operating Margin
9.9%
-31.7%
Net Margin
5.6%
-29.4%
Revenue YoY
0.0%
16.9%
Net Profit YoY
163.7%
3.4%
EPS (diluted)
$0.30
$-0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MYE
MYE
TWST
TWST
Q4 25
$204.0M
$103.7M
Q3 25
$205.4M
Q2 25
$209.6M
Q1 25
$206.8M
Q4 24
$203.9M
Q3 24
$205.1M
Q2 24
$220.2M
Q1 24
$207.1M
Net Profit
MYE
MYE
TWST
TWST
Q4 25
$11.3M
$-30.5M
Q3 25
$7.1M
Q2 25
$9.7M
Q1 25
$6.8M
Q4 24
$4.3M
Q3 24
$-10.9M
Q2 24
$10.3M
Q1 24
$3.5M
Gross Margin
MYE
MYE
TWST
TWST
Q4 25
33.2%
52.0%
Q3 25
33.4%
Q2 25
33.7%
Q1 25
33.4%
Q4 24
32.3%
Q3 24
31.8%
Q2 24
34.3%
Q1 24
31.0%
Operating Margin
MYE
MYE
TWST
TWST
Q4 25
9.9%
-31.7%
Q3 25
8.6%
Q2 25
9.5%
Q1 25
8.1%
Q4 24
7.2%
Q3 24
-2.3%
Q2 24
10.8%
Q1 24
5.3%
Net Margin
MYE
MYE
TWST
TWST
Q4 25
5.6%
-29.4%
Q3 25
3.5%
Q2 25
4.6%
Q1 25
3.3%
Q4 24
2.1%
Q3 24
-5.3%
Q2 24
4.7%
Q1 24
1.7%
EPS (diluted)
MYE
MYE
TWST
TWST
Q4 25
$0.30
$-0.50
Q3 25
$0.19
Q2 25
$0.26
Q1 25
$0.18
Q4 24
$0.11
Q3 24
$-0.29
Q2 24
$0.28
Q1 24
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MYE
MYE
TWST
TWST
Cash + ST InvestmentsLiquidity on hand
$45.0M
$197.9M
Total DebtLower is stronger
$345.8M
Stockholders' EquityBook value
$294.2M
$456.1M
Total Assets
$851.3M
$638.1M
Debt / EquityLower = less leverage
1.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MYE
MYE
TWST
TWST
Q4 25
$45.0M
$197.9M
Q3 25
$48.0M
Q2 25
$41.3M
Q1 25
$35.3M
Q4 24
$32.2M
Q3 24
$29.7M
Q2 24
$37.3M
Q1 24
$32.7M
Total Debt
MYE
MYE
TWST
TWST
Q4 25
$345.8M
Q3 25
$361.2M
Q2 25
$370.8M
Q1 25
$383.4M
Q4 24
$375.0M
Q3 24
$387.5M
Q2 24
$400.1M
Q1 24
$400.6M
Stockholders' Equity
MYE
MYE
TWST
TWST
Q4 25
$294.2M
$456.1M
Q3 25
$286.6M
Q2 25
$284.6M
Q1 25
$277.4M
Q4 24
$277.5M
Q3 24
$275.6M
Q2 24
$294.6M
Q1 24
$291.7M
Total Assets
MYE
MYE
TWST
TWST
Q4 25
$851.3M
$638.1M
Q3 25
$864.1M
Q2 25
$862.7M
Q1 25
$883.8M
Q4 24
$860.8M
Q3 24
$905.0M
Q2 24
$951.6M
Q1 24
$947.1M
Debt / Equity
MYE
MYE
TWST
TWST
Q4 25
1.18×
Q3 25
1.26×
Q2 25
1.30×
Q1 25
1.38×
Q4 24
1.35×
Q3 24
1.41×
Q2 24
1.36×
Q1 24
1.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MYE
MYE
TWST
TWST
Operating Cash FlowLast quarter
$22.6M
$-24.8M
Free Cash FlowOCF − Capex
$18.9M
$-34.8M
FCF MarginFCF / Revenue
9.3%
-33.5%
Capex IntensityCapex / Revenue
1.8%
9.6%
Cash ConversionOCF / Net Profit
1.99×
TTM Free Cash FlowTrailing 4 quarters
$67.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MYE
MYE
TWST
TWST
Q4 25
$22.6M
$-24.8M
Q3 25
$25.8M
Q2 25
$28.3M
Q1 25
$10.1M
Q4 24
$27.3M
Q3 24
$17.3M
Q2 24
$14.3M
Q1 24
$20.3M
Free Cash Flow
MYE
MYE
TWST
TWST
Q4 25
$18.9M
$-34.8M
Q3 25
$21.5M
Q2 25
$24.7M
Q1 25
$2.0M
Q4 24
$20.2M
Q3 24
$10.1M
Q2 24
$9.9M
Q1 24
$14.6M
FCF Margin
MYE
MYE
TWST
TWST
Q4 25
9.3%
-33.5%
Q3 25
10.5%
Q2 25
11.8%
Q1 25
1.0%
Q4 24
9.9%
Q3 24
4.9%
Q2 24
4.5%
Q1 24
7.0%
Capex Intensity
MYE
MYE
TWST
TWST
Q4 25
1.8%
9.6%
Q3 25
2.1%
Q2 25
1.7%
Q1 25
3.9%
Q4 24
3.5%
Q3 24
3.5%
Q2 24
2.0%
Q1 24
2.8%
Cash Conversion
MYE
MYE
TWST
TWST
Q4 25
1.99×
Q3 25
3.63×
Q2 25
2.92×
Q1 25
1.49×
Q4 24
6.36×
Q3 24
Q2 24
1.40×
Q1 24
5.79×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MYE
MYE

Industrial$64.3M32%
Auto Aftermarket$51.7M25%
Infrastructure$34.0M17%
Food And Beverage$23.2M11%
Vehicle$17.9M9%
Consumer$12.9M6%

TWST
TWST

Industrial Chemicals$37.2M36%
Diagnostics$35.3M34%
Food Or Agriculture$12.8M12%
Academic Research$12.2M12%
Health Care$6.1M6%

Related Comparisons